This award is open to manufacturers or UK distributors of injectable products for the UK aesthetics market. Finalists will be chosen from products that support a wide range of indications and can show evidence of good safety and efficacy, optimum duration and tangible benefits over similar products on the market. This category is only open to products that have been available for a year or more. You are encouraged to keep your entry concise and clear; bullet points and the use of formatting options such as bold, underlines and italics are encouraged to ensure your entry is easy to digest for judges. A strict character limit of 1,700 (including spaces) is enforced for each question and you must not exceed this; however, your entry does not have to meet it. References are included in the character count, although you may supply a reference list as part of your supplementary materials if it exceeds the character count. The winner will be selected from the finalists using a combination of Aesthetics reader votes and judges’ scores. Voting will constitute a 30% share of the final score.
RRS consists of un-crosslinked hyaluronic acid which supports and stimulates the extra-cellular matrix. In addition some ranges also carry Silicium which stimulates the local production of collagen. Alongside these two main substrates, there are up to 72 added amino acids, nucleotides and polyphenols amongst others that then provide a biorevitalisation cocktail.
Easy to use as an injectable and compatible with multiple delivery systems, RRS® offers stable, durable and rapid treatment results. RRS® is an extremely versatile product range and can be tailored to the patients’ needs, skin condition and lifestyle. The RRS® range can also be used in multiple modalities depending on the qualification and profession of the practitioner with consistent and predictable results. This adds a significant value both therapeutically and commercially to what may be already offered.
Skintech, the creator is a company that prides itself in offering both laboratory and clinically tested products. There are robust medical studies that are available to refer to that demonstrate both efficacy and safety making the range an absolutely obvious choice. There are very few mesotherapy ranges available to the aesthetic practitioner and those that do exist do not have the level of studies and testing that RRS has to support it .
Profhilo® is a revolutionary BDDE-free, thermally stabilized hyaluronic acid product for skin remodelling produced by IBSA Italia with the patented NAHYCO™ technology.
Profhilo has proven to be much appreciated for its characteristics of safety, high spreadability and cohesivity. These qualities have been shown to be very effective in treating skin laxity in areas such as face, neck, décolletage, hands, arms, abdomen and knees.
Profhilo is made from IBSA’s FDA approved SHYALT® ultrapure hyaluronic acid raw material and the final product is CE marked.
Concentration of 64mg/2ml of H-HA and L-HA.
Patients can expect a tissue remodelling, tissue hydration and improvement in the skin laxity with effects lasting six months as demonstrated by various clinical studies.
Despite being unique product, Profhilo is universally recognised within the industry as third injectable option alongside toxin and dermalfillers, available in the top clinics, chains as well as individual practitioners.
A true game-ganger available in the UK since 2016.Profhilo holds a high efficacy and safety profile.
Ellansé: Safe, natural, regenerative & long lasting. Ellansé is a unique bio-stimulating dermal filler that provides both instant and gradual results. Increased volume, contouring and definition occurs immediately post-injection from CMC gel; however, the result achieved is maintained due to production of Type 1 collagen in response to the PolyCaproLactone in the product stimulating fibroblasts in the areas Ellansé is placed.
When young Type 1 collagen is abundant in the body, providing the infrastructure for naturally abundant hyaluronic acid and elastin, creating firm, youthful skin. Type 1 collagen loss starts from 27, and we lose 1.5% a year. By 50, 50% of our Type 1 collagen has diminished, making Ellansé an ideal filler for patients in their 20s-30s looking for jawline and chin definition, for 40s for the first signs of jowls and marionette lines, to midface and temporal volume loss for patients in their 50s.
The Ellansé range has four variations, S, M, L, E, which allows doctors to customise treatment according to length of time results will last (1-4 years). The S & M (1-2 years) can be used globally for full-face rejuvenation. The 3-4-year product (L&E) is a good option for younger patients looking for chin and nose reshaping.
Teosyal RHA is the first hyaluronic acid dermal filler specifically designed to respect facial dynamics, with a unique and innovative technology developed to mimic the natural hyaluronic acid within our skin.
This technology is designed to allow our gels to work in synchronisation with patients’ facial expressions and provide a natural looking result whilst remaining undetectable.
Specific products from our RHA range of dermal fillers can be used to obtain a global lifting effect such as restoration of lost volume in the mid-face, projection of the chin, correction of expression lines, plumping and redefinition of the lips and finally smoothing of fine lines.
The technology of Teosyal RHA has recently been credited, by receipt of FDA approval of RHA 2, 3 & 4 for moderate to severe dynamic wrinkles and folds. Making history in the HA market as the first company to have three dermal filler products approved for FDA at one time, this accreditation reinforces Teoxane’s commitment to delivering science-based, high-quality and innovative HA products to the global market.